Pfizer, Flynn accused of charging the NHS ‘unfairly high prices’ for anti-epilepsy drug
UK Competition and Markets Authority provisionally finds drug companies broke competition law
Read More
Tag: Flynn
UK slaps Pfizer with record £84.2m fine for unfair drug pricing
Pfizer and Flynn Pharma have been fined nearly £90 million by the UK’s Competition and Markets Authority (CMA) for deliberately unbranding an anti-epilepsy drug to enable excessive price hikes.
Read More
- FDA approves new high dose Spinraza regimen for SMA
- Viridian reports positive results from elegrobart phase 3 trial
- Cure Parkinson’s convenes expert panel to assess £2 million combination therapy funding call
- Kygevvi approved in Europe as first treatment for TK2d
- Tozorakimab shows significant benefit in two major COPD trials
